BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33616718)

  • 1. Overexpression of poliovirus receptor is associated with poor prognosis in head and neck squamous cell carcinoma patients.
    Lim SM; Hong MH; Ha SJ; Hwang D; Chae S; Koh YW; Choi EC; Kim SH; Kim DH; Yoon SO; Kim HR
    J Cancer Res Clin Oncol; 2021 Sep; 147(9):2741-2750. PubMed ID: 33616718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of PVR and PD-L1 and its association with prognosis in surgically resected squamous cell lung carcinoma.
    Lee JB; Hong MH; Park SY; Chae S; Hwang D; Ha SJ; Shim HS; Kim HR
    Sci Rep; 2021 Apr; 11(1):8551. PubMed ID: 33879814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression level of PD-L1 is involved in ALDH1A1-mediated poor prognosis in patients with head and neck squamous cell carcinoma.
    Zhou AL; Wang X; Yu W; Yang L; Wei F; Sun Q; Wang Y; Kou F; Dong R; Ren X; Zhang X
    Pathol Res Pract; 2020 Sep; 216(9):153093. PubMed ID: 32825960
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Pai SI; Cohen EEW; Lin D; Fountzilas G; Kim ES; Mehlhorn H; Baste N; Clayburgh D; Lipworth L; Resteghini C; Shara N; Fujii T; Zhang J; Stokes M; Wang H; Twumasi-Ankrah P; Wildsmith S; Khaliq A; Melillo G; Shire N
    J Transl Med; 2019 Dec; 17(1):429. PubMed ID: 31878938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
    Ngamphaiboon N; Chureemas T; Siripoon T; Arsa L; Trachu N; Jiarpinitnun C; Pattaranutaporn P; Sirachainan E; Larbcharoensub N
    Med Oncol; 2019 Jan; 36(2):21. PubMed ID: 30666437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma.
    Okada S; Itoh K; Ishihara S; Shimada J; Kato D; Tsunezuka H; Miyata N; Hirano S; Teramukai S; Inoue M
    Surg Oncol; 2018 Jun; 27(2):259-265. PubMed ID: 29937180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spatial Intratumoral Heterogeneity Expression of PD-L1 Antigen in Head and Neck Squamous Cell Carcinoma.
    Hirshoren N; Al-Kharouf I; Weinberger JM; Eliashar R; Popovtzer A; Knaanie A; Fellig Y; Neuman T; Meir K; Maly A; Vainer GW
    Oncology; 2021; 99(7):464-470. PubMed ID: 33789303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.
    Yang WF; Wong MCM; Thomson PJ; Li KY; Su YX
    Oral Oncol; 2018 Nov; 86():81-90. PubMed ID: 30409325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.
    Zandberg DP; Algazi AP; Jimeno A; Good JS; Fayette J; Bouganim N; Ready NE; Clement PM; Even C; Jang RW; Wong S; Keilholz U; Gilbert J; Fenton M; Braña I; Henry S; Remenar E; Papai Z; Siu LL; Jarkowski A; Armstrong JM; Asubonteng K; Fan J; Melillo G; Mesía R
    Eur J Cancer; 2019 Jan; 107():142-152. PubMed ID: 30576970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of PD-1/PD-L1 in head and neck squamous cell carcinoma and its clinical significance.
    Chen SW; Li SH; Shi DB; Jiang WM; Song M; Yang AK; Li YD; Bei JX; Chen WK; Zhang Q
    Int J Biol Markers; 2019 Dec; 34(4):398-405. PubMed ID: 31674884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Negative prognostic behaviour of PD-L1 expression in tongue and larynx squamous cell carcinoma and its significant predictive power in combination with PD-1 expression on TILs.
    Ahmadvand S; Norouzi LA; Mohammadi Y; Safaei A; Khademi B; Motiee-Langroudi M; Ghaderi A
    BMC Immunol; 2024 Jan; 25(1):7. PubMed ID: 38229027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune gene expression in head and neck squamous cell carcinoma patients.
    Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
    Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia dynamics on FMISO-PET in combination with PD-1/PD-L1 expression has an impact on the clinical outcome of patients with Head-and-neck Squamous Cell Carcinoma undergoing Chemoradiation.
    Rühle A; Grosu AL; Wiedenmann N; Mix M; Stoian R; Niedermann G; Baltas D; Werner M; Weber WA; Kayser G; Nicolay NH
    Theranostics; 2020; 10(20):9395-9406. PubMed ID: 32802199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic and clinicopathological significance of PD-L1 and tumor infiltrating lymphocytes in hypopharyngeal squamous cell carcinoma.
    Hu C; Tian S; Lin L; Zhang J; Ding H
    Oral Oncol; 2020 Mar; 102():104560. PubMed ID: 31923855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TLR9 Mediated Tumor-Stroma Interactions in Human Papilloma Virus (HPV)-Positive Head and Neck Squamous Cell Carcinoma Up-Regulate PD-L1 and PD-L2.
    Baruah P; Bullenkamp J; Wilson POG; Lee M; Kaski JC; Dumitriu IE
    Front Immunol; 2019; 10():1644. PubMed ID: 31379843
    [No Abstract]   [Full Text] [Related]  

  • 18. PD-1 and PD-L1 expression in HNSCC primary cancer and related lymph node metastasis - impact on clinical outcome.
    Schneider S; Kadletz L; Wiebringhaus R; Kenner L; Selzer E; Füreder T; Rajky O; Berghoff AS; Preusser M; Heiduschka G
    Histopathology; 2018 Oct; 73(4):573-584. PubMed ID: 29742291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PD-L1 expression associates with low T-cadherin expression and poor prognosis in human papillomavirus-negative head and neck squamous cell carcinoma.
    Wang Q; Zhao Y; Chen Y; Chen Y; Song X; Zhang L; He Q; Ye B; Wu L; Huang X; Wang D
    Head Neck; 2023 May; 45(5):1162-1171. PubMed ID: 36939297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression predicts longer disease free survival in high risk head and neck cutaneous squamous cell carcinoma.
    Roper E; Lum T; Palme CE; Ashford B; Ch'ng S; Ranson M; Boyer M; Clark J; Gupta R
    Pathology; 2017 Aug; 49(5):499-505. PubMed ID: 28666643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.